Transparency Market Research (TMR)
has published a new report on the prostate cancer
therapeutics market for the forecast period
of 2019–2027. According
to the report, the global prostate cancer therapeutics market was valued
at ~US$
9.6 Bn in 2018, and is projected to expand at a CAGR
of ~8% from 2019 to 2027. To Know More
about TMRs Unique Offerings for Prostate Cancer Therapeutics Market, Request a Sample here
Prostate Cancer Therapeutics Market:
Overview
·
Prostate
cancer is the most common non-cutaneous cancer occurring worldwide. New cases
of prostate cancer account for one-third of all male cancer diagnoses and 10% of
all deaths, globally.
·
Increase
in cancer screening with prostate-specific antigen (PSA) is in part responsible
for high localized staging of the disease at the time of diagnosis.
·
A
majority of patients eventually become hormone refractory; however, the time in
which androgen-insensitive clones emerge could range from months to years from
the initiation of androgen-depravation therapy-ADT.
·
A
number of different treatment modalities have been examined for prostate
cancer. Each treatment has potential advantages as well as therapeutic
limitations.
·
Emerging
clinical data regarding long-term safety and early evidence of clinical
benefits are likely to lead to development of novel modality of therapy for prostate
cancer, which will be available across the globe.
·
Vaccines
or antibodies administered in combination with radiation, chemotherapy,
small-molecule targeted therapy, or perhaps even other immunotherapy could
generate substantial synergistic effects.
·
Chemotherapy
has long been a leading treatment for prostate cancer. When androgen-targeted
signaling agents such as abiraterone and enzalutamide first emerged, their
relatively favorable toxicity profile combined with efficacy led some to
speculate that chemotherapy would no longer be necessary in prostate cancer.
Request
a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6562
Rise in Prevalence of Prostate Cancer
and Launch of Promising Emerging Therapies to Drive Market
·
Increase
in life expectancy in developed countries has increased the geriatric
population, which, in turn, has led to the high incidence of prostate cancer.
According to the Prostate Cancer Foundation, a majority of prostate cancer
cases are diagnosed in men over 65. Hence, consistent rise in the geriatric
population and sedentary lifestyles of people in developed countries augment
the prevalence of prostate cancer across the globe. This increases the need and
demand for prostate cancer therapeutics. According to the Urology Care
Foundation, around 1 in 7 men is diagnosed with prostate cancer, and
approximately one in 35 men succumb to the disease.
·
Various
emerging diagnostic techniques have revolutionized prostate cancer detection at
an early stage. The measurement of prostate-specific antigen (PSA) levels has
helped the diagnosis of prostate cancer. Promising new therapies in phase II
and phase III trials include new cytotoxic agents, hormonal agents, and other
antiprostate-specific membrane antigen therapies. According to the Mayo
Foundation for Medical Education and Research (MFMER), a combination of
hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) treatment
strategies can provoke a focused immune response against prostate tumors.
·
Prominent
players in the prostate cancer treatment market are emphasizing on R&D and
the manufacture of therapeutics for the long-term survival of patients.
Castration-resistant prostate cancer (CRPC) has driven the approvals of
effective & potent systemic agents as first- and second-line treatments.
Currently, numerous molecular agents are in the early phase of clinical trials
for the treatment of prostate cancer. As of May 2016, the FDA
had approved 13 new indications and four novel drugs in oncology, some of which
are considered as first-in-class therapies.
Request for Analysis of COVID19
Impact on Prostate Cancer Therapeutics Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=6562
Hormone Therapy to Dominate Market
·
In
terms of therapy, the global prostate cancer therapeutics market has been
classified into hormone therapy (luteinizing hormone-releasing hormone analogs,
luteinizing hormone-releasing hormone antagonists, and antiandrogens),
chemotherapy (systemic chemotherapy, regional chemotherapy), biologic therapy,
and targeted therapy.
·
The
hormone therapy segment dominated the market in 2018, and the trend
is likely to continue during the forecast period.
·
Launch
of new products in antiandrogens and luteinizing hormone-releasing hormone
antagonists are projected to boost the growth of the hormone therapy segment.
Hospital Pharmacies to be Promising
Distribution Channels
·
In
terms of distribution channel, the global prostate cancer therapeutics market
has been divided into hospital pharmacies, retail pharmacies, online sales, and
others. The hospital pharmacies segment is projected to be a highly lucrative
segment of the global prostate cancer therapeutics market during the forecast
period.
·
The
hospital pharmacies segment is anticipated to grow at a rapid pace, as a majority
of prostate cancer treatments are performed in hospitals, and these settings
offer easy reimbursement procedures.
Request
For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=6562
North America to Dominate Global
Prostate Cancer Therapeutics Market
·
In
terms of region, the global prostate cancer therapeutics market has been
segmented into five major regions: North America, Europe, Asia Pacific, Latin
America, and the Middle East & Africa.
·
North
America dominated the global prostate cancer therapeutics market in 2018, followed
by Europe. Rise in the prevalence of prostate cancer among the geriatric
population in North America has led to a high number of patients visiting
hospitals. Hence, increase in the number of consultation with physicians for
prostate cancer therapeutics is also projected to increase market growth in
North America during the forecast period. North America’s high market share is
attributed to a large number of prostate cancer patients. It is a primary
region for players in the global prostate cancer therapeutic products market.
·
Europe
was the second-largest market for prostate cancer therapeutics in terms of
share in 2018. The region has witnessed an increase in the
demand for prostate cancer therapeutic products and rising prevalence of the
disease. However, the expiration of patents of major drugs is likely to hamper
market growth in Europe.
·
The
prostate cancer therapeutics market in Asia Pacific is projected to expand at a
high CAGR from 2019 to 2027. This can be attributed to an increase
in awareness about the disease.
Buy now Prostate Cancer
Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=6562<ype=S
Growth Strategies of Key Players in
Prostate Cancer Therapeutics Market
·
The
global prostate cancer therapeutics market is fragmented in terms of number of
players. Key players operating in the global market are Amgen, Inc.,
Johnson & Johnson (Janssen Biotech, Inc.), Pfizer, Inc., AstraZeneca,
AbbVie, Inc., Bayer AG, Ipsen Group, Sanofi, Endo Pharmaceuticals, Inc., and
Sanpower Group (Dendreon Corporation).
·
Pfizer,
Inc. was the second-largest shareholder of the global prostate cancer
therapeutics market in 2018. It is expected to dominate the
global market in terms of supply of prostate cancer therapeutic products.
·
Janssen
Biotech (Johnson & Johnson) accounted for the third-largest share of the
global prostate cancer therapeutics market in 2018. Zytiga was the
major brand sold for the treatment of prostate cancer.
More
Trending Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/rising-diabetic-patients-pool-prompts-high-demand-for-smart-insulin-pens-market-estimated-to-be-valued-at-us-70-4-mn-by-2027-end-tmr-301316368.html
https://www.prnewswire.com/news-releases/profound-ramp-up-in-agricultural-production-using-ngs-technology-fosters-growth-in-global-ngs-sample-preparation-market-technology-to-benefit-animal-sciences-as-well-tmr-301242277.html
https://www.prnewswire.com/news-releases/companies-in-radiation-dermatitis-market-leverage-nanomaterials-for-developing-novel-therapies-for-wound-healing-valuation-to-touch-us-700-mn-by-2030-tmr-301243337.html
About Us
Transparency
Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of
quantitative forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of analysts,
researchers, and consultants use proprietary data sources and various tools and
techniques to gather and analyze information.
TMR’s data
repository is continuously updated and revised by a team of research experts so
that it always reflects the latest trends and information. With extensive
research and analysis capabilities, Transparency Market Research employs
rigorous primary and secondary research techniques to develop distinctive data
sets and research material for business reports.
Contact
Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com